Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Murphy (Glasgow, United Kingdom), G. Jayasekera (Glasgow, United Kingdom), J. Mullin (Glasgow, United Kingdom), L. Gallagher (Glasgow, United Kingdom), Y. Dempsie (Glasgow, United Kingdom), D. Welsh (Glasgow, United Kingdom). Macitentan treatment improves the dysfunctional right ventricle in a sugen/hypoxic rat model of pulmonary hypertension. 5056

Member's Comments

No comment yet.

Related content which might interest you: Improvements in the dysfunctional right ventricle with Macitentan treatment in a sugen/hypoxic rat model of pulmonary hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Urocortin-2 improves right ventricular function and attenuates experimental pulmonary arterial hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Carvedilol partially reverses maladaptive remodeling and improves function of the right ventricle (RV) in experimentally-induced pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 How prostacyclin therapy improves right ventricular function in pulmonary arterial hypertension Source: Eur Respir J, 50 (2) 1700764; 10.1183/13993003.00764-2017 Year: 2017 Right ventricular reserve in a piglet model of chronic pulmonary hypertension Source: Eur Respir J 2015; 45: 709-717 Year: 2015 Lodenafil improves hemodynamics and right ventricular remodeling in monocrotaline-induced model of pulmonary arterial hypertension in rats Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Macitentan in pulmonary hypertension due to left ventricular dysfunction Source: Eur Respir J, 51 (2) 1701886; 10.1183/13993003.01886-2017 Year: 2018 Bosentan combined with sildenafil prevents right ventricular hypoxia in pulmonary arterial hypertension Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 More on the right ventricle in pulmonary hypertension Source: Eur Respir J 2015; 45: 33-35 Year: 2015 Isolated diastolic dysfunction of right ventricle: stress-induced pulmonary hypertension Source: Eur Respir J 2008; 31: 475-476 Year: 2008 Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension Source: Eur Respir J, 49 (6) 1700007; 10.1183/13993003.00007-2017 Year: 2017 The PPAR-β/δ agonist GW0742 reverses right venticular hypertrophy in a chronically hypoxic rat model of pulmonary hypertension Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 The role of the right ventricle in pulmonary arterial hypertension Source: Eur Respir Rev 2011; 20: 243-253 Year: 2011 Cystamine and sildenafil in treatment of right ventricular hypertrophy in rats with pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Exercise training in pulmonary hypertension improves beta-adrenergic signaling of the right ventricle Source: Annual Congress 2009 - Pulmonary circulation II Year: 2009 Combining bosentan and sildenafil improves mitochondrial capacity and restores right ventricular contractility in established pulmonary hypertension Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 Right ventricular stiffness impairs right atrial function in pulmonary arterial hypertension Source: Virtual Congress 2020 – Right ventricular function and pulmonary hypertension Year: 2020 The evaluation of right and left ventricular dysfunction in COPD patients with pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 250s Year: 2001